Biodesix Debt to Equity Ratio 2020-2024 | BDSX
Current and historical debt to equity ratio values for Biodesix (BDSX) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Biodesix debt/equity for the three months ending September 30, 2024 was 1.30.
| Biodesix Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2024-09-30 | $0.08B | $0.03B | 2.69 |
| 2024-06-30 | $0.08B | $0.04B | 2.20 |
| 2024-03-31 | $0.09B | $-0.01B | -16.85 |
| 2023-12-31 | $0.10B | $0.01B | 20.64 |
| 2023-09-30 | $0.09B | $-0.00B | -61.02 |
| 2023-06-30 | $0.09B | $-0.01B | -12.10 |
| 2023-03-31 | $0.08B | $0.01B | 16.76 |
| 2022-12-31 | $0.07B | $0.02B | 3.51 |
| 2022-09-30 | $0.07B | $-0.00B | -22.77 |
| 2022-06-30 | $0.07B | $0.01B | 8.81 |
| 2022-03-31 | $0.05B | $0.01B | 6.92 |
| 2021-12-31 | $0.06B | $0.02B | 2.86 |
| 2021-09-30 | $0.07B | $0.02B | 4.61 |
| 2021-06-30 | $0.08B | $0.03B | 2.95 |
| 2021-03-31 | $0.08B | $0.04B | 2.17 |
| 2020-12-31 | $0.08B | $0.04B | 1.94 |
| 2020-09-30 | $0.30B | $-0.26B | -1.18 |
| 2020-06-30 | $0.00B | $0.00B | 0.00 |
| 2020-03-31 | $0.00B | $0.00B | 0.00 |
| 2019-12-31 | $0.00B | 0.00 | |
| 2019-09-30 | $0.00B | $0.00B | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $0.212B | $0.049B |
| Biodesix Inc. is a data-driven diagnostic solutions company. It offers blood-based tests across the lung cancer continuum of care. The company also offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as develops and commercializes companion diagnostics. Biodesix Inc. is based in Boulder, Colorado. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $86.493B | 10.73 |
| Cencora (COR) | United States | $43.979B | 16.54 |
| DiDi Global (DIDIY) | China | $22.358B | 0.00 |
| Natera (NTRA) | United States | $21.439B | 0.00 |
| ICON (ICLR) | Ireland | $17.593B | 15.67 |
| Viatris (VTRS) | United States | $14.801B | 4.56 |
| Avantor (AVTR) | United States | $14.538B | 21.80 |
| Revvity (RVTY) | United States | $13.672B | 23.75 |
| BioMerieux (BMXMF) | France | $12.468B | 0.00 |
| CochLear (CHEOY) | Australia | $12.010B | 0.00 |
| Solventum (SOLV) | United States | $11.499B | 0.00 |
| Doximity (DOCS) | United States | $10.879B | 64.03 |
| Medpace Holdings (MEDP) | United States | $10.651B | 30.01 |
| Charles River Laboratories (CRL) | United States | $9.526B | 18.41 |
| HealthEquity (HQY) | United States | $8.292B | 41.60 |
| Sonic Healthcare (SKHHY) | Australia | $8.215B | 0.00 |
| Bausch + Lomb (BLCO) | Canada | $6.290B | 29.28 |
| Amplifon S.p.A (AMFPF) | Italy | $5.864B | 29.89 |
| Sotera Health (SHC) | United States | $3.838B | 20.53 |
| Organon (OGN) | United States | $3.794B | 3.83 |
| BrightSpring Health Services (BTSG) | United States | $3.037B | 64.59 |
| Surgery Partners (SGRY) | United States | $2.671B | 30.45 |
| Concentras Parent (CON) | United States | $2.608B | 0.00 |
| Ardent Health Partners (ARDT) | United States | $2.294B | 0.00 |
| GeneDx Holdings (WGS) | United States | $2.126B | 0.00 |
| Premier (PINC) | United States | $2.067B | 10.76 |
| Alignment Healthcare (ALHC) | United States | $2.055B | 0.00 |
| PACS (PACS) | United States | $1.995B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.711B | 44.90 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.651B | 0.00 |
| Teladoc Health (TDOC) | United States | $1.594B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.246B | 0.00 | |
| Progyny (PGNY) | United States | $1.237B | 25.05 |
| Embecta (EMBC) | United States | $1.179B | 8.24 |
| Pediatrix Medical (MD) | United States | $1.177B | 11.52 |
| CareDx (CDNA) | United States | $1.149B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.891B | 6.03 |
| QDM (QDMI) | Hong Kong, SAR China | $0.790B | 20.69 |
| Agilon Health (AGL) | United States | $0.787B | 0.00 |
| SBC Medicals (SBC) | United States | $0.553B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.550B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.509B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.444B | 0.00 |
| DocGo (DCGO) | United States | $0.431B | 16.23 |
| Enhabit (EHAB) | United States | $0.385B | 33.30 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.276B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.268B | 0.00 |
| LifeMD (LFMD) | United States | $0.213B | 0.00 |
| MultiPlan (MPLN) | United States | $0.198B | 0.00 |
| Beauty Health (SKIN) | United States | $0.185B | 0.00 |
| Nutex Health (NUTX) | United States | $0.173B | 0.00 |
| ModivCare (MODV) | United States | $0.163B | 8.83 |
| So-Young (SY) | China | $0.093B | 15.80 |
| Ascend Wellness Holdings (AAWH) | United States | $0.081B | 0.00 |
| NeueHealth (NEUE) | United States | $0.062B | 1.65 |
| IceCure Medical (ICCM) | Israel | $0.051B | 0.00 |
| Singular Genomics Systems (OMIC) | United States | $0.049B | 0.00 |
| OncoCyte (OCX) | United States | $0.036B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.025B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.025B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.024B | 0.00 |
| Oncology Institute (TOI) | United States | $0.017B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.009B | 0.00 |
| XWELL (XWEL) | United States | $0.008B | 0.00 |
| KindlyMD (KDLY) | United States | $0.006B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.006B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.004B | 0.00 | |
| NewGenIvf Group (NIVF) | Thailand | $0.003B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| Aclarion (ACON) | United States | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.001B | 0.00 |